From: Axitinib as a third or further line of treatment in renal cancer: a single institution experience
Characterstics | Median | Range |
---|---|---|
Age | 55,4 | 30,2-73,5 |
 | N | % |
Sex | ||
 Male | 11 | 50 |
 Female | 11 | 50 |
Histology | ||
 ccRCC | 17 | 77,3 |
 non-ccRCC | 5 | 22,7 |
Nephrectomy | ||
 Yes | 22 | 100 |
 No | 0 | 0 |
Fuhrman grade | ||
  < 3 | 6 | 27,3 |
  ≥ 3 | 13 | 59,1 |
 NA | 3 | 13,6 |
Heng prognostic group at 1st line | ||
 Good | 6 | 27,3 |
 Intermediate | 13 | 59,1 |
 Poor | 1 | 4,5 |
 NA | 2 | 9,1 |
Heng prognostic group at axitinib line | ||
 Good | 0 | 0 |
 Intermediate | 9 | 40,9 |
 Poor | 11 | 50 |
 NA | 2 | 9,1 |
Axitinb line of treatment | ||
 3 | 12 | 54,5 |
 4 | 4 | 18,2 |
  > 4 | 6 | 27,3 |
Previous treatments | ||
 TKI only | 1 | 4,5 |
 TKI/IO | 2 | 9,1 |
 TKI/mTOR inhibitor | 19 | 85,3 |
No of previous TKIs received | ||
  < 2 | 11 | 50 |
  ≥ 2 | 11 | 50 |
No of metastatic sites at axitinib treatment | ||
 solitary | 4 | 18,2 |
 multiple | 18 | 81,8 |
Sites of metastases at axitinib treatment | ||
 lymph nodes | 12 | 54,5 |
 lung | 19 | 85,3 |
 liver | 9 | 40,9 |
 bone | 5 | 22,7 |
 local relapse | 8 | 36,4 |